{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336700","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-08-06T11:06:30+00:00","discovered_at":"2026-08-06T11:10:07.335831+00:00","generated_at":"2026-08-06T11:11:21.788720+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cullinan Therapeutics Q2 2026 net loss $53.7M; cash $356M; pipeline on track","bullets":["Net loss $53.7M vs $70.1M YoY; R&D expenses $44.4M vs $61.0M; G&A $12.8M vs $14.8M.","Cash and investments $356M as of June 30, 2026; runway into 2029.","CLN-049 Phase 2 in R/R AML to start Q3 2026 after positive FDA End-of-Phase 1 meeting.","CLN-978 multi-dose data in RA Q3 2026, SLE Q4 2026; Phase 2 expansion early 2027.","Zipalertinib NDA accepted; PDUFA Feb 27, 2027; Cullinan eligible for $30M on 2L approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336700","json":"https://secwatch.observer/filing/0001193125-26-336700.json","markdown":"https://secwatch.observer/filing/0001193125-26-336700.md","text":"https://secwatch.observer/filing/0001193125-26-336700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/0001193125-26-336700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526336700/cgem-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:11:21.788720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}